MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter
MustGrow Biologics (OTCQB: MGROF), a biological and regenerative agriculture solutions provider, reported strong Q2-2025 financial results. The company achieved revenue of $2.8 million, including $312,832 from TerraSante™ biofertility product sales in the U.S., compared to no revenue in Q2-2024.
The company improved its gross profit margin to 20.9% in Q2-2025, up from 14.3% in Q1-2025. TerraSante™ sales in Q2 tripled the entire 2024 sales volume, with inventory selling out due to growing demand. The company maintained a stable financial position with $1.8 million in cash and equivalents and $1.8 million in inventory as of June 30, 2025. The quarter resulted in a net loss of $1.1 million, or $0.02 per basic share.
MustGrow Biologics (OTCQB: MGROF), fornitore di soluzioni biologiche e per l’agricoltura rigenerativa, ha comunicato solidi risultati finanziari del 2° trimestre 2025. La società ha registrato ricavi per 2,8 milioni di dollari, comprensivi di 312.832$ derivanti dalle vendite del biofertilizzante TerraSante™ negli Stati Uniti, rispetto a nessun ricavo nel 2° trimestre 2024.
Il margine di profitto lordo è salito al 20,9% nel 2° trimestre 2025, rispetto al 14,3% del 1° trimestre 2025. Le vendite di TerraSante™ nel 2° trimestre hanno triplicato il volume totale del 2024, esaurendo l’inventario a causa della crescente domanda. Al 30 giugno 2025 la società manteneva una posizione finanziaria stabile con 1,8 milioni di dollari in liquidità e equivalenti e 1,8 milioni di dollari in inventario. Il trimestre ha chiuso con una perdita netta di 1,1 milioni di dollari, pari a 0,02$ per azione base.
MustGrow Biologics (OTCQB: MGROF), proveedor de soluciones biológicas y de agricultura regenerativa, informó sólidos resultados financieros del 2T-2025. La compañía alcanzó ingresos de 2,8 millones de dólares, incluyendo 312.832$ por ventas del biofertilizante TerraSante™ en EE. UU., frente a cero ingresos en el 2T-2024.
El margen de beneficio bruto mejoró hasta el 20,9% en el 2T-2025, desde el 14,3% en el 1T-2025. Las ventas de TerraSante™ en el 2T triplicaron el volumen total de 2024, agotando el inventario debido a la creciente demanda. Al 30 de junio de 2025, la compañía mantenía una posición financiera estable con 1,8 millones de dólares en efectivo y equivalentes y 1,8 millones en inventario. El trimestre cerró con una pérdida neta de 1,1 millones de dólares, o 0,02$ por acción básica.
MustGrow Biologics (OTCQB: MGROF)는 생물학적 및 재생농업 솔루션 제공업체로서 강력한 2025 회계연도 2분기 실적을 발표했습니다. 회사는 미국에서의 TerraSante™ 바이오비료 제품 판매로 312,832달러를 포함한 총 매출 280만 달러를 기록했으며, 이는 2024년 2분기 매출이 전무했던 것과 대비됩니다.
회사는 2025년 2분기 매출총이익률을 20.9%로 개선했으며, 이는 2025년 1분기의 14.3%에서 상승한 수치입니다. 2분기 TerraSante™ 판매량은 2024년 전체 판매량의 세 배에 달해 재고가 수요 증가로 소진되었습니다. 2025년 6월 30일 기준 현금 및 현금성자산 180만 달러와 재고 180만 달러로 안정적인 재무상태를 유지했습니다. 해당 분기 순손실은 110만 달러, 주당 기본손실은 0.02달러였습니다.
MustGrow Biologics (OTCQB: MGROF), fournisseur de solutions biologiques et d’agriculture régénérative, a publié de solides résultats financiers du T2-2025. La société a réalisé un chiffre d’affaires de 2,8 millions de dollars, dont 312 832$ provenant des ventes aux États-Unis du biofertilisant TerraSante™, contre aucun revenu au T2-2024.
La marge brute s’est améliorée à 20,9% au T2-2025, contre 14,3% au T1-2025. Les ventes de TerraSante™ au T2 ont triplé le volume total de 2024, entraînant l’épuisement des stocks en raison d’une demande croissante. Au 30 juin 2025, la société affichait une situation financière stable avec 1,8 million de dollars en liquidités et équivalents et 1,8 million de dollars de stocks. Le trimestre s’est soldé par une perte nette de 1,1 million de dollars, soit 0,02$ par action de base.
MustGrow Biologics (OTCQB: MGROF), ein Anbieter biologischer und regenerativer Landwirtschaftslösungen, meldete starke Ergebnisse für Q2-2025. Das Unternehmen erzielte Umsatz in Höhe von 2,8 Millionen US-Dollar, darunter 312.832$ aus dem US-Verkauf des Bio-Düngemittels TerraSante™, gegenüber keinen Einnahmen im Q2-2024.
Die Bruttomarge verbesserte sich im Q2-2025 auf 20,9%, nach 14,3% im Q1-2025. Die TerraSante™-Verkäufe im Q2 vervielfachten das gesamte Verkaufsvolumen von 2024, sodass der Bestand aufgrund der steigenden Nachfrage ausverkauft war. Zum 30. Juni 2025 hielt das Unternehmen eine stabile Finanzlage mit 1,8 Millionen US-Dollar an liquiden Mitteln und Äquivalenten sowie 1,8 Millionen US-Dollar an Lagerbeständen. Das Quartal schloss mit einem Nettoverlust von 1,1 Millionen US-Dollar bzw. 0,02$ je Stammaktie.
- First-time revenue generation of $2.8 million in Q2-2025 vs. no revenue in Q2-2024
- Gross profit margin improved to 20.9% in Q2-2025 from 14.3% in Q1-2025
- TerraSante™ U.S. sales in Q2 tripled entire 2024 sales volume
- Strong demand leading to complete sellout of TerraSante™ inventory
- Net loss of $1.1 million for Q2-2025
- Limited cash position of $1.8 million as of June 30, 2025
- Q2 and Q3 represent slower 'shoulder season' for Canadian sales division
Investor Webcast: Thursday, August 28th at 4:00pm ET / 1:00pm PT
Register/View Here: https://us02web.zoom.us/webinar/register/2017556244178/WN_xF4GBBCXThC3_f1GZYAkZg
Please join/register at least 5 minutes prior to the call.
Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.
Saskatoon, Saskatchewan--(Newsfile Corp. - August 27, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended June 30, 2025. For complete details, please refer to the Q2-2025 Condensed Interim Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.
Key Financial Highlights:
- Sales revenue of
$2.8 million was recorded (including$312,832 from sales of TerraSanteTM biofertility product in the U.S.) in Q2-2025 vs. no revenue in Q2-2024 - Gross profit of
$594,718 equating to a20.9% gross profit margin in Q2-2025 (up from14.3% in Q1-2025)(1) - Cash and equivalents on hand as at June 30, 2025 was
$1.8 million with inventory of$1.8 million - Net loss for the three-month period ended June 30, 2025 was
$1.1 million and the net loss per share was$0.02 (basic) for the same period
"Our second quarter 2025 showed a gross profit margin improvement over the first quarter end March 31, 2025 resulting from sales of TerraSanteTM biofertility product in the U.S.," stated Corey Giasson, President and CEO of MustGrow. "We sold out of our TerraSanteTM inventory in the U.S. during this second quarter, which was triple our TerraSanteTM sales in all of 2024. The TerraSanteTM initial sales ramp-up has started and we are working on producing more product to meet the growing demand. For our Canadian sales and distribution division, NexusBioAg, Q2 and Q3 are considered the slower 'shoulder season' whereas Q1 and Q4 are traditionally stronger sales periods for Canadian farmers purchasing crop inputs. Margins in this segment have picked up from the first quarter and we are looking to finish the year with a strong Q4."
The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S.
Notes:
1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV: MGRO) and has approximately 52.4 million common shares issued and outstanding and 59.4 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
MustGrow's Forward-Looking Statements
Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2025 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264159
FAQ
What were MustGrow's (MGROF) Q2 2025 revenue and profit margins?
How did MustGrow's TerraSante™ product perform in Q2 2025?
What is MustGrow's (MGROF) current financial position as of Q2 2025?
What are the seasonal trends in MustGrow's Canadian sales division?
How much was MustGrow's (MGROF) earnings per share in Q2 2025?
